These findings identify IL-22 as an important regulator of intestinal GLP-1 production and glucose homeostasis during diet-induced obesity and highlight IL-22-GLP-1 signaling as a potential therapeutic axis for metabolic disorders. This evidence concerns the gene IL22 and Other metabolic disease.